Argenica Therapeutics (ASX:AGN) has disclosed the Chair's Address and Managing Director Presentation delivered at its Annual General Meeting held at 2:00PM WST on 19 November 2026, outlining the Phase 2 clinical trial results for its lead drug candidate xaranetide in acute ischaemic stroke and preclinical traumatic brain injury studies.
Key Points
- The Phase 2 clinical trial of xaranetide (formerly ARG-007) met its primary safety objective in acute ischaemic stroke patients undergoing endovascular thrombectomy.
- A post-hoc analysis correcting for baseline stroke severity identified statistically significant improvements in FDA-validated functional outcomes in patients with larger infarct cores.
- Argenica is finalising the design of a targeted late-stage AIS trial in consultation with its global stroke Clinical Advisory Committee and potential pharmaceutical partners.
- Xaranetide has demonstrated significant neuroprotection across mild, moderate and severe traumatic brain injury and concussion models in preclinical studies.
Phase 2 Trial Safety and Efficacy Outcomes
According to the filing, the Phase 2 clinical trial of xaranetide in acute ischaemic stroke patients presenting to emergency departments and undergoing endovascular thrombectomy successfully met its primary objective of demonstrating safety in that patient population. The trial also explored the drug's effect on a number of predefined efficacy measures and identified more severe stroke patients showing a treatment benefit with xaranetide. The company described demonstrating safety in this patient population as a significant milestone in neurology drug development.
Post-Hoc Analysis in Patients with Larger Infarct Cores
The filing states that a post-hoc analysis correcting for baseline stroke severity identified statistically significant improvements in FDA-validated functional outcomes in patients with larger infarct cores. The company noted that these patients typically have the worst outcomes following stroke, and characterised them as the group with the most to gain from an effective neuroprotective treatment. On the basis of the trial safety and functional efficacy data, Argenica said it is finalising the design of a targeted late-stage acute ischaemic stroke trial in consultation with its global stroke Clinical Advisory Committee and potential pharmaceutical partners.
Preclinical Traumatic Brain Injury and Concussion Studies
The filing disclosed that during the year xaranetide demonstrated significant neuroprotection across a number of preclinical traumatic brain injury and concussion studies. The company stated it now has a growing body of evidence across mild, moderate and severe TBI injury models and is considering next steps to advance xaranetide's development in this indication. The AGM presentation also referenced a concurrent filing relating to FDA feedback, which the Managing Director and CEO, Liz Dallimore, was stated to have addressed during her presentation at the meeting.





Please wait processing your request...